| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10967401 | Vaccine | 2013 | 9 Pages |
Abstract
New 'MenB' vaccines could substantially reduce disease in England and be cost-effective if competitively priced, particularly if the vaccines can prevent carriage as well as disease. These results are relevant to other countries, with a similar epidemiology to England, considering the introduction of a new 'MenB' vaccine.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Hannah Christensen, Matthew Hickman, W. John Edmunds, Caroline L. Trotter,